83. CES 2026 | Las Vegas

CytoAurora Biotechnologies (Hua Tec International) was honored to participate in today’s CES Innovation Awards ceremony and press conference, engaging with innovative teams and industry partners from around the world and witnessing the presentation of forward-looking technologies on the global stage.

At CES 2026, our technology received international recognition and was featured in extensive coverage by multiple global media outlets, including interviews from the United Kingdom, South Korea, Thailand, Brazil, and the Netherlands.

Many media representatives showed strong interest in the cancer cell screening system independently developed in Taiwan, with particular focus on its capabilities in technology integration and potential for clinical applications.

The next post will further outline the practical application scenarios of the Nano CAST™ Cancer Solution and the key aspects highlighted by media coverage.

醫華生技很榮幸能夠參與今日 CES Innovation Awards 的授獎典禮及新聞發布會，與來自全球的創新團隊與產業夥伴交流，共同見證前瞻技術於國際舞台上的發表。

本次於 CES 2026，我們的技術成果獲得國際肯定，並受到多家國際媒體大篇幅報導，涵蓋來自英國、韓國、泰國、巴西、荷蘭等多個國家的媒體採訪。

多數媒體對於由台灣自主研發的癌細胞篩檢系統展現高度關注，特別著墨於該系統在技術整合能力與臨床應用潛力上的發展方向。

下一篇將進一步說明 Nano CAST™ 癌細胞辨識系統 的實際應用場景及媒體的關注重點。